Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 11/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CDK4 | P11802 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439644 | 1.00 | CDK9 (0.55) | CDK9CDK1CDK4CDK2CCNT1 | |
| SCHEMBL12501692 | 0.87 | CDK9 (0.51) | CDK9CDK1CDK4CDK2CCNT1 | |
| SCHEMBL12501693 | 0.87 | CDK9 (0.51) | CDK9CDK1CDK4CDK2CCNT1 | |
| SCHEMBL1439848 | 0.82 | USP30 (0.50) | CDK9CCNT1ABL1MAPK8MAPK10 | |
| SCHEMBL1439849 | 0.82 | USP30 (0.50) | CDK9CCNT1ABL1MAPK8MAPK10 | |
| SCHEMBL1944749 | 0.82 | CCNT1 (0.54) | CDK9CDK4CDK2CCNT1ABL1 | |
| SCHEMBL1944753 | 0.82 | CCNT1 (0.54) | CDK9CDK4CDK2CCNT1ABL1 | |
| SCHEMBL12827050 | 0.80 | CDK9 (0.46) | CDK9ABL1NTRK1MAPK8MAPK10 | |
| SCHEMBL16042236 | 0.79 | CDK9 (0.46) | CDK9ABL1NTRK1MAPK8MAPK10 | |
| SCHEMBL16042238 | 0.79 | CDK9 (0.46) | CDK9ABL1NTRK1MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473502-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011026917-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | CDK9 6/4885CDK1 2/4885CDK4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.